Cellectis S.A. - ADR Peer Comparison

$1.16

$-0.10 (-7.92%)

As on 29-Oct-2026 13:32EDT

Market cap

$99 Mln

Revenue (TTM)

$57 Mln

P/E Ratio

--

P/B Ratio

3.9

Div. Yield

0 %

Edit

	Cellectis S.A. - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Market cap ($ Mln)	99	2,698	2,496	1,595	793
Revenue ($ Mln)	57	450	549	121	366
Net Profit ($ Mln)	-65.35	-188.21	17.88	-57.76	9.27
Net Margin (%)	-115.48	-41.86	3.26	-47.60	2.53
RoE (%)	-111.74	-28.46	1.43	-9.91	3.39
Price to Earnings	--	--	143.60	--	86.15
Price-To-Book	3.85	4.56	2.25	3.65	2.95

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Cellectis S.A. - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Operating Revenue	56.59	449.61	549.12	120.79	366.45
Cost of Revenue	14.31	195.71	548.01	19.21	49.36
Gross Profit	63.15	269.08	212.72	12.07	330.63
Operating Expenses	104.13	517.90	35.89	154.86	304.74
Operating Profit (EBIT)	-61.86	-264.00	-34.78	-118.11	12.35
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-69.15	-190.72	20.08	-57.14	15.84
Provision for Tax	-3.80	-2.51	1.66	0.62	6.57
Profit after Tax (Net Income)	-65.35	-188.21	17.88	-57.50	9.27
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Cellectis S.A. - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Shareholder's Funds	41.07	607.04	1,260.78	568.41	270.49
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	91.34	39.17	186.25	123.56	104.25
Current Liabilities	134.96	428.58	275.21	81.11	93.25
Total Liabilities	324.72	1,172.38	1,753.10	784.68	499.81

Assets ($ Mln)

	Cellectis S.A. - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Non-Current Assets	82.95	160.76	183.02	575.59	187.30
Current Assets	184.42	914.04	1,553.41	197.49	280.69
Total Assets	324.72	1,172.38	1,753.10	784.68	499.81
Total Debt*	84.57	254.58	94.51	127.33	113.30
Net Current Assets	49.46	485.45	0.00	116.38	187.44

Cashflow ($ Mln)

	Cellectis S.A. - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Cash From Operating Activities	-40.14	-150.79	-64.66	-49.95	54.71
Cash Flow from Investing Activities	-29.58	307.87	-29.41	0.12	26.25
Cash from Financing Activities	-16.20	72.35	7.84	147.34	1.50
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Cellectis S.A. - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
ROCE (%)	-32.32	-18.15	41.92	-15.42	0.77
ROE (%)	-111.74	-28.46	1.43	-10.06	3.39
ROA (%)	-14.15	-12.55	0.66	-6.60	1.69
EBIT Margin (%)	-131.76	-41.09	-6.33	-42.43	8.34
Net Margin (%)	-115.48	-41.86	3.26	-47.60	2.53
Cash Profit Margin (%)	0.00	0.00	--	--	0.00

Growth Ratios

	Cellectis S.A. - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Revenue Growth (%)	0.52	5.10	-8.81	602.33	-99.61
EBIT Growth (%)	-46.93	11.36	-76.55	17.93	523.06
Net Profit Growth (%)	-10.76	11.44	-96.17	43.71	-99.68
EPS Growth (%)	-10.45	-1.87	-96.17	47.43	-96.78
Book Value Growth (%)	-57.85	-25.05	2.54	-6.65	7.71

Valuation Ratios

	Cellectis S.A. - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Price / Earnings	-7.18	-11.11	5.08	-13.58	469.58
Price / Book Value	6.40	2.73	1.88	2.32	4.83
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-9.96	-9.39	-25.56	-18.38	36.65
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Cellectis S.A. - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Debt to Equity	1.28	0.00	0.00	0.19	0.34
Short term debt to equity ratio	0.20	0.40	0.02	0.02	0.03
Current Ratio	1.37	2.13	5.64	2.43	3.01
Quick Ratio	1.37	1.92	5.50	2.09	2.31
Interest Coverage	-7.21	-30.87	-19.05	-4.06	2.08

Operating Efficiency Ratios

	Cellectis S.A. - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Debtors to sales (%)	24.11	16.23	21.41	47.25	15.55
Asset Turnover	0.12	0.30	0.20	0.14	0.67
Receivable days	121.05	77.60	104.79	380.35	51.78
Inventory Days	--	109.55	49.57	791.94	492.02
Payable days	669.97	231.78	47.68	931.00	466.91
Cash Conversion Cycle	--	-44.63	106.67	241.30	76.89

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly